6d
Medpage Today on MSNSemaglutide Tied to Small Risk of Potentially Blinding Eye ConditionThe use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...
1d
GlobalData on MSNSemaglutide shortage ends as FDA sets deadline for compoundersWith Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
20hon MSN
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results